Posts

Showing posts with the label pad treatment

Voyager's Arrival Bodes Well for Boston Sci's Ranger DCB - Medical Device and Diagnostics Industry

Voyager's Arrival Bodes Well for Boston Sci's Ranger DCB    Medical Device and Diagnostics Industry

Reewarm PTX drug-coated balloon in the treatment of femoropopliteal artery disease: A multi-center, randomized controlled trial in China - DocWire News

Reewarm PTX drug-coated balloon in the treatment of femoropopliteal artery disease: A multi-center, randomized controlled trial in China    DocWire News

News from TCT: VOYAGER PAD and paclitaxel, STEMI in COVID-19 and more - Healio

News from TCT: VOYAGER PAD and paclitaxel, STEMI in COVID-19 and more    Healio

Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials - DocWire News

Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials    DocWire News

Health Report- New treatment for arthritis - YourErie

Health Report- New treatment for arthritis    YourErie

Nonpharmacological Management of Diabetic Foot Ulcers: An Update - DocWire News

Nonpharmacological Management of Diabetic Foot Ulcers: An Update    DocWire News

'I am hopeful': Coliseum Medical Centers participating in clinical trial for possible COVID-19 treatment - 13WMAZ.com

'I am hopeful': Coliseum Medical Centers participating in clinical trial for possible COVID-19 treatment    13WMAZ.com

BioWorld MedTech Patent Highlights: Week 41 | 2020-10-16 - BioWorld Online

BioWorld MedTech Patent Highlights: Week 41 | 2020-10-16    BioWorld Online

Talk of the County reader opinion: Trump gets premium treatment while continuing to promise ‘big beautiful health care plan’ - Chicago Tribune

Talk of the County reader opinion: Trump gets premium treatment while continuing to promise ‘big beautiful health care plan’    Chicago Tribune

Boil-water notice lifted from Texas city where microbe found - KEYE TV CBS Austin

Boil-water notice lifted from Texas city where microbe found    KEYE TV CBS Austin

Surmodics' Pounce Thrombus Retrieval System Gets FDA Nod - Yahoo Finance

Surmodics' Pounce Thrombus Retrieval System Gets FDA Nod    Yahoo Finance

Four takeaways from Orioles GM Mike Elias’ season-ending media session - Baltimore Sun

Four takeaways from Orioles GM Mike Elias’ season-ending media session    Baltimore Sun

Donating plasma for COVID-19 patients through American Red Cross - KENS5.com

Donating plasma for COVID-19 patients through American Red Cross    KENS5.com

Safety of day-case endovascular interventions for peripheral arterial disease in a rural, underserved area - DocWire News

Safety of day-case endovascular interventions for peripheral arterial disease in a rural, underserved area    DocWire News

Microseismic monitoring helps optimize fracturing, multipad drilling - Midland Reporter-Telegram

Microseismic monitoring helps optimize fracturing, multipad drilling    Midland Reporter-Telegram

Avinger's $5.2 Million Common Stock Offering – Global Legal Chronicle - Global Legal Chronicle

Avinger's $5.2 Million Common Stock Offering – Global Legal Chronicle    Global Legal Chronicle

Yale VAMOS Program Provides Holistic Vascular Care - yale.edu

Yale VAMOS Program Provides Holistic Vascular Care    yale.edu

JanOne Advances its Potential Peripheral Artery Disease and Covid-19 Vascular Inflammation Treatment Towards Trial Readiness - Cath Lab Digest

JanOne Advances its Potential Peripheral Artery Disease and Covid-19 Vascular Inflammation Treatment Towards Trial Readiness    Cath Lab Digest

Pluristem Launches FDA-Cleared COVID-19 Expanded Access Program, Enabling Patient Treatment Outside of Clinical Trial - GlobeNewswire

Pluristem Launches FDA-Cleared COVID-19 Expanded Access Program, Enabling Patient Treatment Outside of Clinical Trial    GlobeNewswire

Viveve Announces Positive Primary Efficacy Data from its SUI Feasibility Study and Positive Preclinical Outcomes that Support the Company's New Sham Tip for Pivotal PURSUIT Trial - BioSpace

Viveve Announces Positive Primary Efficacy Data from its SUI Feasibility Study and Positive Preclinical Outcomes that Support the Company's New Sham Tip for Pivotal PURSUIT Trial    BioSpace